The information-motivation-behavioral skills model of antiretroviral adherence and its applications

Current HIV/AIDS Reports

Volumn 5, Issue 4, 2008, Pages 193-203

  Fisher, Jeffrey D ^a   Amico, K Rivet ^a   Fisher, William A ^a   Harman, Jennifer J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BEHAVIOR; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; HEALTH BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTIVATION; PATIENT COMPLIANCE; QUESTIONNAIRE; REVIEW; RISK REDUCTION; SKILL; BEHAVIOR THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; INFORMATION DISSEMINATION; METHODOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL MODEL; STATISTICS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BEHAVIOR THERAPY; HIV INFECTIONS; HIV-1; HUMANS; INFORMATION DISSEMINATION; MODELS, PSYCHOLOGICAL; MOTIVATION; PATIENT COMPLIANCE;

EID: 58149154471     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0028-y     Document Type: Review

References (56)

1. US Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Atlanta: Centers for Disease Control and Prevention; 2002.
2. Joint United Nations Programme on HIV/AIDS: 2006 Report on the global AIDS epidemic: executive summary. Available at http://www.unaids.org/en/ HIV_data/ 2006GlobalReport/default.asp. Accessed June 4, 2006.
3. Jensen-Fangel A, Pederson L, Pederson C, et al.: Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004, 18:89-97.
4. Palella FJ, Deloria-Knoll M, Chimiel JS, et al.: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003, 138:620-626.
5. Pradier C, Carrieri P, Bentz L, et al.: Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs. Int J STD AIDS 2001, 12:324-328.
6. Roca B, Gomez CJ, Arnedo A: Adherence, side effects, and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients. J Infect 2000, 41:50-54.
7. Shor-Posner G, Lecusay R, Miguez-Burbano MJ, et al.: Quality of life measures in the Miami HIV-1 infected drug abusers cohort: relationship to gender and disease status. J Subst Abuse 2000, 11:395-404.
8. Turpin JA: The next generation of HIV/AIDS drugs: novel and developmental anti-HIV drugs and targets. Expert Rev Anti Infect Ther 2003, 1:97-128.
9. Altice FL, Friedland GH: The era of adherence to HIV therapy. Ann Intern Med 1998, 129:503-504.
10. •• Bangsberg DR, Kroetz DL, Deeks SG: Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007, 4:65-72. Study results strongly support the need for more refined consideration of optimal versus suboptimal adherence relative to the relation between certain kinds of medication regimens and the development of resistance.
11. Nieuwkerk PT, Sprangers MA, Burger DM, et al.: Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001, 161:1962-1968.
12. Pradier C, Carrieri P, Bentz L, et al.: Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs. Int J STD AIDS 2001, 12:324-328.
13. de la Rosa R, Ruiz-Mateos E, Rubio A, et al.: Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004, 53:95-101.
14. Holzemer WL, Corless IB, Nokes KM, et al.: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999, 13:185-197.
15. Bangsberg DR, Moss AR, Deeks SG: Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004, 53:696-699.
16. Sethi AK, Celentano DD, Gange SJ, et al.: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003, 37:1112-1118.
17. Belzer ME, Fuchs DN, Luftman GS, et al.: Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 1999, 25:316-319.
18. Rigsby MO, Rosen MI, Beauvais JE, et al.: Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000, 15:841-847.
19. Singh N, Berman SM, Swindells S, et al.: Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999, 29:824-830.
20. Spire B, Duran S, Souville M, et al.: Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to dynamic approach. Soc Sci Med 2002, 54:1481-1496.
21. Pach A 3rd, Cerbone FG, Gerstein DR.: A qualitative investigation of antiretroviral therapy among injection drug users. AIDS Behav 2003, 7:87-100.
22. Ross L, Lim ML, Liao Q, et al.: Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007, 8:1-8.
23. SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008, 22:625-635.
24. Wainberg MA, Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
25. •• Gardner EM, Sharma S, Peng G, et al.: Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008, 22:75-82. This study calls attention to the potential within a given individual for varying rates of adherence to different medications within a full antiretroviral regimen.
26. Kahn JO, Walker BD: Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998, 339:133-139.
27. Moatti JP, Souteyrand Y: HIV/AIDS social and behavioural research: past advances and thoughts about the future. Soc Sci Med 2000, 50:1519-1532.
28. Maggiolo F, Airoldi M, Kleinloog HD, et al.: Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 2007, 8:282-292.
29. Perno CF, Moyle G, Tsoukas C, et al.: Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008, 80:565-576.
30. Chesney MA, Farmer P, Leander F, et al.: Human immunodeficiency virus and acquired immunodeficiency syndrome. In Adherence to Long-Term Therapies: Evidence for Action. Edited by Sabate E. Geneva: World Health Organization; 2003:95-106.
31. Kelly JA, Otto-Salaj LL, Sikkema KJ, et al.: Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Health Psychol 1998, 17:310-319.
32. Duran S, Spire B, Raffi F, et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001, 2:38-45.
33. Tseng A, Foisy M, Fletcher D: Handbook of HIV Drug Therapy. Toronto: The Toronto Hospital; 1998.
34. Chesney MA, Ickovics J, Hecht FM, et al.: Adherence: a necessity for successful HIV combination therapy. AIDS 1999, 13(Suppl A):S271-S278.
35. Chesney MA, Morin M, Sherr L: Adherence to HIV combination therapy. Soc Sci Med 2000, 50:1599-1605.
36. •• Munro S, Lewin S, Swart T, Volmink J: A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC Public Health 2007, 7:104. A comprehensive review of health promotion theory applied to adherence across diverse conditions and medications.
37. •• Fisher JD, Fisher WA, Amico R, Harman JJ: An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol 2006, 25:462-473. This article thoroughly outlines the IMB model for HAART adherence and provides initial empirical support.
38. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press; 1991.
39. Pearson CR, Micek MA, Simoni JM, et al.: Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique: development and implementation. J Acquir Immune Defic Syndr 2006, 43:S134-S141.
40. Pearson CR, Micek MA, Simoni JM, et al.: Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007, 46:238-244.
41. Fisher JD, Fisher WA: Changing AIDS risk behavior. Psychol Bull 1992, 111:455-474.
42. Amico KR, Toro-Alfonso J, Fisher JD: An empirical test of the information, motivation, behavioral skills model of antiretroviral therapy adherence. AIDS Care 2005, 17:661-673.
43. Starace F, Massa A, Amico KR, Fisher JD: Adherence to antiretroviral therapy: an empirical test of the information-motivation-behavioral skills model. Health Psychology 2006, 25:153-162.
44. Amico KR, Barta W, Konkle-Parker DJ, et al.: The information- motivation-behavioral skills model of ART adherence in a Deep South HIV positive clinic sample. AIDS Behav 2007 Sep 18 [Epub ahead of print].
45. Margolin A, Avants S, Warburton L, et al.: A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol 2003, 22:223-228.
46. Kalichman S, Cherry J, Cain D: Nurse-delivered antiretroviral treatment adherence intervention for people with low literacy skills and living with HIV/AIDS. J Assoc Nurses AIDS Care 2005, 16:3-15.
47. Mannheimer SB, Morse E, Matts JP, et al.: Community programs for clinical research on AIDS. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S41-S47.
48. Wagner G, Kanouse D, Golinelli D, et al.: Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS 2006, 20:1295-1302.
49. Parsons JT, Golub SA, Rosof E, et al.: Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Aquir Immune Defic Syndr 2007, 46:433-450.
50. Ware NC, Wyatt MA, Bangsberg DR: Examining theoretical models of adherence for validity in resource-limited settings: a heuristic approach. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S18-S22.
51. Haberer J: Measurement of adherence to ART in HIV-infected school-aged children in Uganda. National Institute of Mental Health grant 1R21MH083306-01. March 14, 2008.
52. Kalichman SC: HIV treatment adherence/risk reduction integrated. National Institute of Mental Health grant 5R01MH071164-04. April 1, 2005.
53. Catz S: Patient portal to support treatment adherence. National Institute of Mental Health grant 1R01MH081750-01A1. July 7, 2008.
54. Cornman DH, Christie S, Amico KR, et al.: Options Intervention Protocol Manual: A Step-by-Step Guide to Risk Reduction Counseling with PLWHA. Available at http://www.chip.uconn.edu/int/Protocol%20Manual%20de signed%206-28-07%20COMPLETE%20for%20WEB.pdf. Accessed August 2008.
55. Fisher JD, Fisher WA, Cornman, DH, et al.: Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Aquir Immune Defic Syndr 2006, 41:44-52.
56. Prochaska JO, DiClemente CC, Norcross JC: In search of how people change: applications to addictive behaviors. Am Psychol 1992, 42:1112-1114.